Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Fish and Richardson
AstraZeneca
Colorcon
Johnson and Johnson
Medtronic
Teva
QuintilesIMS

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,192,576

« Back to Dashboard

Which drugs does patent 9,192,576 protect, and when does it expire?

Patent 9,192,576 protects CYCLOSET and is included in one NDA.

This patent has fourteen patent family members in eleven countries.
Summary for Patent: 9,192,576
Title:Bromocriptine formulations
Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycerine control in the treatment of type 2 diabetes.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI), Bowe; Craig Michael (Encinitas, CA), Stearns; Paul Clark (San Diego, CA), Weston; Laura Jean (Escondido, CA)
Assignee: VeroScience LLC (Tiverton, RI)
Application Number:14/088,269
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 9,192,576

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,192,576

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,522,117 Bromocriptine formulations ➤ Sign Up
8,431,155 Bromocriptine formulations ➤ Sign Up
9,700,555 Bromocriptine formulations ➤ Sign Up
8,613,947 Bromocriptine formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
Cerilliant
AstraZeneca
Accenture
Federal Trade Commission
US Department of Justice
Teva
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.